αβ-TCR/CD19 depleted HSC therapy (Washington University School of Medicine)

N/A

Report date: 2025/01/26 17:41:44

Base Information

Drug Nameαβ-TCR/CD19 depleted HSC therapy (Washington University School of Medicine)

Drug Alias NameEx Vivo Expanded HSC Therapy (Washington University School of Medicine)αβ-TCR/CD19 depleted HSC therapy (Washington University School of Medicine)

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionStem cells stimulantsImmunomodulatorsHaematopoiesis stimulants

TargetsUpdating

Therapy Area/Indications +[1] N/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesWashington University

China Registration ClassN/A

Develop Information

Active CompaniesWashington University

Inactive CompaniesN/A

Active Indications +[1] N/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A